Takahashi N.,Akita University |
Wakita H.,Red Cross |
Miura M.,Akita University |
Scott S.A.,Mount Sinai School of Medicine |
And 16 more authors.
Clinical Pharmacology and Therapeutics | Year: 2010
Despite the outstanding results generally obtained with imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML), some patients show a poor molecular response. To evaluate the relationship between steady-state trough plasma IM concentration (IM-Cmin) and clinical response in CML patients, we integrated data from six independent Japanese studies. Among 254 CML patients, the mean IM-Cmin was 1,010.5ng/ml. Importantly, IM-Cmin was significantly higher in patients who achieved a major molecular response (MMR) than in those who did not (P = 0.002). Multivariate analysis showed that an MMR was associated with both age (odds ratio (O=R) = 0.97 (0.958-0.995); P = 0.0153) and with IM-Cmin (OR = 1.0008 (1.0003-1.0015); P = 0.0044). Given that patients with IM-Cmin values 1,002ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients. © 2010 American Society for clinical Pharmacology and Therapeutics.